Inhibition of human cytochrome CYP1 enzymes by flavonoids of St. John's wort
Introduction
Our research focus is the potential for bioflavonoids to act as therapeutic and/or preventative agents in prostate cancer via inhibition of the CYP1 cytochrome P450 enzymes, which have been implicated in carcinogenesis (Chun and Kim, 2003, McFadyen et al., 2004). The P450 superfamily of genes is involved in the oxidation and excretion of both endogenous and exogenous nonpolar compounds in the body. The human CYP1 gene family is comprised of CYP1A1, CYP1A2, and CYP1B1. CYP1A2 is expressed primarily in liver, CYP1A1 is expressed in both liver and extrahepatic tissues, whereas CYP1B1 is primarily expressed extrahepatically. The CYP1s are involved in bioactivating polycyclic aromatic hydrocarbons (PAHs), heterocyclic amines, and estradiol to mutagenic and carcinogenic intermediates (Murray et al., 2001). In the prostate, CYP1B1 message has been detected in normal (Finnstrom et al., 2001) and benign prostatic hyperplasia (Luo et al., 2002) and is up-regulated in malignant prostate tissue (Chaib et al., 2001, Carnell et al., 2004). In a Japanese population a CYP1B1 polymorphism at codon 119 has been associated with prostatic carcinogenesis (Tanaka et al., 2002). This polymorphism has also been associated with the highest catalytic bioactivation of estradiol (Hanna et al., 2000). More recently, Chang et al. (2003) identified a frequent haplotype in CYP1B1 that was associated with an increased risk for prostate cancer. Together these studies, implicate CYP1B1 as a potential therapeutic target for reducing development of prostate cancer.
Inhibiting CYP1B1 selectively could be considered chemoprotective for several reasons. First, Shimada et al. (1999) found that recombinant human CYP1B1 was more active than CYP1A1 in metabolizing benzo(a)pyrene (BaP) to the proximate toxicant BaP-7,8-diol. In addition, human CYP1B1 is an estradiol hydroxylase, acting primarily at the C-4 position. CYP1A1, in contrast, has activity at the C-2, C-6α and C-15α positions of estradiol (Hayes et al., 1996). In rodent tissues, including the Noble rat prostate, estrogen induces tumors when estradiol is primarily converted to the 4-hydroxyestradiol metabolite, yet tumors fail to develop where 2-hydroxylation predominates (Cavalieri et al., 2002). Lastly, CYP1B1 can detoxify cancer drugs, such as flutamide and possibly docetaxel, which reduces their cytotoxic potential and effectiveness (Rochat et al., 2001, McFadyen et al., 2001, Bournique and Lemarie, 2002). This is particularly significant because CYP1B1 is over-expressed in a variety of human tumors compared to adjacent noncancerous cells (McFadyen et al., 2001). Therefore, the hypothesis guiding this study was that a bioflavonoid could be potentially anti-carcinogenic if it could inhibit CYP1B1's ability to metabolize PAHs and estrogen to toxic intermediates and/or decrease CYP1B1's ability to detoxify cancer drugs. Because prostate cancer typically has a long latency period and develops in older men, this disease may be particularly amenable to chemopreventive approaches (Saleem et al., 2003).
St. John's wort (Hypericium perforatum) is an herbal product widely used as an over the counter remedy for mild to moderate depression. It contains a number of classes of pharmacologically active compounds including napthodianthrones, flavonoids, phloroglucinols, procyanidins, tannins, essential oils, amino acids, phenylpropanes, xanthones and other water-soluble compounds (Greeson et al., 2001). It is well known that some of the flavonoids in St. John's wort exert a modulating role on the metabolism of drugs and xenobiotics by acting as inducers or inhibitors of cytochrome P450s. Evidence is prevalent that St. John's wort induces CYP3A, one of the most important human drug metabolizing enzymes and the cause of adverse drug reactions in some patients (Vogel, 2001). Other commercially available St. John's wort extracts and individual components have been investigated for their effects on CYP1A1, CYP2D6, CYP2C9, CYP3A4, CYP1A2 and CYP2C19 (Obach, 2000). Prior to our work, little has been reported about the effects of flavonoids found in St. John's wort on CYP1B1 specifically.
In this present study, we characterized eight flavonoids: quercetin, amentoflavone, kaempferol, myricetin, quercitrin, isoquercetin, rutin, and apigenin (Fig. 1) for their inhibition of recombinant CYP1B1 and CYP1A1. Apigenin, while not a component of St. John's wort, is a monomer of amentoflavone and was included in these experiments to determine if the effects of amentoflavone would reflect its degradation into monomers. While none of the flavonoids were significantly selective for CYP1B1 compared to CYP1A1, apigenin especially was a relatively potent CYP1B1 inhibitor. In addition, we showed that myricetin, apigenin, kaempferol, and quercetin can inhibit EROD activity, a conventional assay for assessment of CYP1 enzyme activity, in the 22Rv1 human prostate cancer cell line. By distinguishing the relative roles of cytochrome P450s (specifically CYP1s) in human prostate cancer cell lines, new therapies or chemoprotective strategies against prostate cancer formation may emerge.
Section snippets
Methods
Recombinant human CYP1A1 and CYP1B1 + reductase SUPERSOMES were obtained from BD Biosciences (Bedford, MA). Amentoflavone (purity 99.83%) and isoquercetin (99%) were obtained from Chromadex, Inc. (Santa Ana, CA). Quercetin (98%), myricetin (85%), kaempferol (90%), quercitrin dihydrate (85%), apigenin (95%) and rutin hydrate (95%) were obtained from Sigma (St. Louis, MO). Stock solutions (0.1 mM) of flavonoids were prepared in dimethyl sulfoxide (Sigma) and stored at room temperature. The
Results
Eight flavonoids were tested for their inhibition of EROD activity. Maximal EROD activities in the DMSO controls were 851 ± 42 and 333 ± 20 pmol/mg/min for recombinant CYP1A1 and CYP1B1, respectively. Regression curves plotting percent EROD inhibition for each flavonoid from which the IC50s were calculated are shown in Fig. 2. Calculated IC50s for CYP1B1 inhibition ranged from 0.30 ± 0.11 μM for apigenin to 27 ± 15 μM for rutin (Table 1). CYP1A1 IC50s ranged from 4.9 ± 2.7 μM for kaempferol to 38 ± 19 μM for
Discussion
As described in recent reviews (McFadyen et al., 2004, Chun and Kim, 2003), CYP1B1 has become an increasingly popular potential target for cancer therapy and prevention. Our goal was to characterize for the first time the CYP1B1 inhibition potential of a series of flavonoids found in herbal supplements and food. The aim to inhibit CYP1B1 stems from the fact that it is up-regulated in cancer cells, it bioactivates PAHs and estrogen to DNA reactive metabolites, and it can inactivate
Acknowledgements
The authors would like to thank Drs. Robert Speth, John Matthews and Larry Walker (University of Mississippi) for helpful suggestions in the preparation of this manuscript and the inhibition kinetics analyses. This research was supported by funding from American Association of Colleges of Pharmacy and by NIH Grant Number RR016476 from the MFGN INBRE Program of the National Center for Research Resources.
References (53)
- et al.
Flavonoid effects relevant to cancer
J. Nutr.
(2002) - et al.
Target validation of cytochrome P450 CYP1b1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue
Int. H. Tadiat. Oncol. Biol. Phys.
(2004) - et al.
Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis
Neoplasia
(2001) - et al.
Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1
Toxicology
(2000) - et al.
Characterization of gene expression patterns in 22Rv1 cells for determination of environmental androgenic/antiandrogenic compounds
J. Steroid Biochem. Mol. Biol.
(2003) - et al.
Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man
FEBS Lett.
(1997) - et al.
Effect of flavonoids on cell cycle progression in prostate cancer cells
Cancer Lett.
(2002) Cancer preventive effects of flavonoids—a review
Biomed. Pharmacother.
(2002)- et al.
Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance
Biochem. Pharmacol.
(2001) - et al.
Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole
Biochem. Pharmacol.
(1997)
Flavonol and flavone intakes in US health professionals
J. Am. Diet Assoc.
CYP1A1 genotype-selective inhibition of benzo[a]pyrene activation by quercetin
Eur. J. Cancer
In vitro assessment of inhibition by natural polyphenols of metabolic activation of procarcinogens by human CYP1A1
Biochem. Biophys. Res. Commun.
Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer
Biochem. Biophys. Res. Commun.
Isozyme- and species-specific susceptibility of cDNA-expressed CYP1A P-450s to different flavonoids
Biochim. Biophys. Acta
Inhibition of CYP1A1-dependent activity by the polynuclear aromatic hydrocarbon (PAH) fluoranthene
Biochem. Pharmacol.
St. John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties
J. Pharm. Pharmacol.
Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers
Pharmacopsychiatry
Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme
Drug Metab. Dispos.
Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer
Carcinogenesis
Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer
Br. J. Cancer
Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents
Med. Res. Rev.
Absorption of kaempferol from endive, a source of kaempferol-3-glucuronids, in humans
Eur. J. Clin. Nutr.
A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer
Integr. Cancer Ther.
Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR
Eur. J. Clin. Invest.
Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics
Drug Metabol. Drug Interact.
Cited by (74)
Content variability of bioactive secondary metabolites in Hypericum perforatum L.
2021, Phytochemistry LettersCitation Excerpt :In H. perforatum, most of them are glycosides of quercetin (Tatsis et al., 2007), among which quercetin-3-O-rutinoside (rutin), myricitrin, quercetin-3-O-galactoside (hyperoside), quercetin-3-O-glucoside (isoquercitrin), and quercitrin. Myricetin and quercetin were found to have antitumoral in vitro activity, showing a good potential for the therapy of prostate cancer (Chaudhary and Willett, 2006). Quercetin was typically found in the highest concentrations in both St. John’s Wort and certain foods (especially onions and apples) (Chaudhary and Willett, 2006).
CYPs-mediated drug-drug interactions on psoralidin, isobavachalcone, neobavaisoflavone and daidzein in rats liver microsomes
2020, Food and Chemical ToxicologyRubus rosifolius varieties as antioxidant and potential chemopreventive agents
2017, Journal of Functional FoodsCitation Excerpt :Other polyphenols present in Rubus species, such as ellagic acid derivatives, have been reported to have significantly greater free radical scavenging ability compared to ascorbic acid, tocopherols and low-molecular weight polyphenols (Szajdek & Borowska, 2008). Phenolic compounds are also known to impart inhibitory effects on the activities of cytochrome P450 (CYP) enzymes (Chaudhary & Willett, 2006). CYP enzymes, a ubiquitous heme-containing superfamily of enzymes that are significant in the metabolism of xenobiotics, are also involved in the primary oxidation of numerous endogenous lipophilic compounds such as fatty acids, steroids and vitamins (Tierney & Kennedy, 2008).
Potential role of CYP1B1 in the development and treatment of metabolic diseases
2017, Pharmacology and TherapeuticsCitation Excerpt :More recently, a potent inhibitor of CYP1B1 (IC50 = 0.043 nM) was synthesized from α-naphthoflavone, and its water-soluble derivative can eliminate the resistance of docetaxel in MCF-7/1B1 cells (Cui et al., 2015). Several flavonoids from St. John's wort also show inhibitory activity on CYP1B1, including quercetin, rutin, apigenin, and amentoflavone (Chaudhary & Willett, 2006). Some CYP1B1 inhibitors, such as kaempferol and isorhamnetin, can also antagonize the expression of AHR (Rajaraman, Yang, Chen, & Chang, 2009), which lead to inhibition of the expression of CYP1B1.